Session 116 - CROI 2009

Session 116 Poster Abstracts
Outcomes of HIV Drug Resistance
Wednesday, 1-2:30 pm
Poster Hall

655	Characterization of Virologic Failures in the Randomized, Controlled, Phase III ARTEMIS Trial in Treatment-naïve Patients: Week-96 Analysis I Dierynck¹, S De Meyer¹, E Lathouwers¹, C Vanden Abeele¹, L Lavreys¹, M-P De Béthune¹, and Gaston Picchio*² ¹Tibotec BVBA, Mechelen, Belgium and ²Tibotec, Yardley, PA, US
656	The Rate of Developing ART Resistance during HIV Viremia on HAART in South Africa Christopher Hoffmann*¹, S Charalambous², J Ledwaba³, G Schwikkard³, K Fielding⁴, G Churchyard², R Chaisson¹, J Sim⁵, L Morris³, and A Grant⁴ ¹Johns Hopkins Univ Sch of Med, Baltimore, MD, US; ²Aurum Inst for Hlth Res, Johannesburg, South Africa; ³Natl Inst for Communicable Diseases, Johannesburg, South Africa; ⁴London Sch of Hygiene and Tropical Med, UK; and ⁵Toga Labs, Johannesburg, South Africa
657	Varied Drug Resistance Profiles following First-line Regimen Failure in the South Africa Antiretroviral Program Carole Wallis*¹, I Sanne¹, F Venter¹, J Mellors², and W Stevens^1,3 ¹Univ of the Witwatersrand, Johannesburg, South Africa; ²Univ of Pittsburgh, PA, US; and ³Natl Hlth Lab Svc, Johannesburg, South Africa
658	Response to Second-line ART in South Africa after Antiretroviral Drug-resistance Testing Richard Murphy*¹, Z Lu¹, H Sunpath², B Wang¹, E Losina¹, M Gordon³, D Ross⁴, H Holst², D Kuritzkes⁵, V Marconi⁶, and South Africa Resistance Cohort Study Team (SARCS) ¹Massachusetts Gen Hosp, Boston, US; ²McCord Hosp, Durban, South Africa; ³Nelson R Mandela Sch of Med, Durban, South Africa; ⁴St Mary`s Hosp, Mariannhill, South Africa; ⁵Brigham and Women`s Hosp, Boston, MA, US; and ⁶Wilford Hall US Air Force Med Ctr, Lackland Air Force Base, TX
659	Virologic Drug Resistance Is Not Associated with AIDS-defining Events or Mortality: An ACTG Longitudindal Linked Randomized Trials Analysis Susan Swindells*¹, H Jiang², L Mukherjee², M Winters³, R Bosch², D Katzenstein³, and the AIDS Clinical Trials Group ¹Univ of Nebraska Med Ctr, Omaha, US; ²Statistical and Data Analysis Ctr, Harvard Sch of Publ Hlth, Boston, MA, US; and ³Stanford Univ Med Ctr, CA, US
660	Clinical and Genotypic Factors Associated with Enhanced Survival among Persistently Viremic Triple ARV Class-experienced Patients in the HIV Outpatient Study Frank Palella Jr*¹, C Armon², J Chmiel¹, K Buchacz³, R Novak⁴, J Brooks³, and the HOPS Investigators ¹Northwestern Univ, Chicago, IL, US; ²Cerner Corp, Vienna, VA, US; ³CDC, Atlanta, GA, US; and ⁴Univ of Illinois, Chicago, US
661	Immune Activation Predicts CD4 T Cell Count and Viremia in Patients with Highly Resistant HIV-1 Infection C Kitchen¹, L Yeghiazarian¹, R Hoh², M McCune², E Sinclaire², J Martin², and Steven Deeks*² ¹Univ of California, Los Angeles, US and ²Univ of California, San Francisco, US
662	Discordance in ARV Resistance Profiles between Blood and Cerebrospinal Fluid Is Associated with Current ARV Use George Hightower*¹, S Letendre¹, S Gibson¹, R Ellis^1,2, C Ignacio¹, R Heaton¹, I Grant^1,2, D Richman^1,2, and D Smith^1,2 ¹Univ of California, San Diego, US and ²San Diego VA Hlthcare System, CA, US
663	Amino Acid Substitutions Selected by Therapy in HIV-2 Protease and Reverse Transcriptase J Cavaco Silva¹, A Miranda¹, J Cabanas¹, M Gonçalves¹, E Valadas², K Mansinho¹, K Van Laethem³, A-M Vandamme³, P Gomes^1,4,5, and Ricardo Jorge Camacho*^1,4 ¹Centro Hospitalar de Lisboa Ocidental, Lisboa, Portugal; ²Hospital de Santa Maria, Lisboa, Portugal; ³Rega Inst for Med Res, Katholieke Univ, Leuven, Belgium; ⁴Instituto de Higiene e Medicina Tropical, Lisboa, Portugal; and ⁵Instituto Superior de Ciências da Saúde Egas Moniz, Almada
664	Higher Levels of Residual Viremia in Treatment-experienced than Naïve Patients with Viremia Suppressed to <50 Copies/mL on Combination ART Ann Wiegand*¹, M Kearney¹, R Patel¹, J Mican², R Dewar³, S Stallings³, C Rehm², J Mellors⁴, J Coffin¹, and F Maldarelli¹ ¹HIV Drug Resistance Prgm, NCI, Frederick, MD, US; ²NIAID, NIH, Bethesda, MD, US; ³SAIC, Frederick, MD, US; and ⁴Univ of Pittsburgh, PA, US
665	A Complex Interplay of Mutations in RT, Env, and Gag Is Required for High-level Resistance to Dual-acting Pyrimidinedione HIV Inhibitors Todd Parsley*, C Buckheit, R Buckheit III, K Watson, and R Buckheit Jr Imquest BioSci, Frederick, MD, US